F Cardoso

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
  2. ncbi Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools
    Robert A Ach
    Molecular Technology Lab, Agilent Laboratories, Agilent Technologies, Santa Clara, CA 95051, USA
    BMC Genomics 8:148. 2007
  3. ncbi Current perspectives of epothilones in breast cancer
    Fatima Cardoso
    Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Eur J Cancer 44:341-52. 2008
  4. ncbi Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
  5. ncbi Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
    F Cardoso
    Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Int J Gynecol Cancer 16:533-7. 2006
  6. ncbi Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer
    Fatima Cardoso
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:364-9. 2004
  7. ncbi Microarray technology and its effect on breast cancer (re)classification and prediction of outcome
    Fatima Cardoso
    Department of Medical Oncology, Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res 5:303-4. 2003
  8. ncbi Targeting the ubiquitin-proteasome pathway in breast cancer
    Fatima Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:148-57. 2004
  9. ncbi Show me the genes - I will tell you who/how to treat!
    Fatima Cardoso
    Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res 7:77-9. 2005
  10. ncbi The MINDACT trial: the first prospective clinical validation of a genomic tool
    Fatima Cardoso
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Mol Oncol 1:246-51. 2007

Detail Information

Publications79

  1. ncbi Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
    ..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms...
  2. ncbi Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools
    Robert A Ach
    Molecular Technology Lab, Agilent Laboratories, Agilent Technologies, Santa Clara, CA 95051, USA
    BMC Genomics 8:148. 2007
    ....
  3. ncbi Current perspectives of epothilones in breast cancer
    Fatima Cardoso
    Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Rue Heger Bordet, 1, 1000 Brussels, Belgium
    Eur J Cancer 44:341-52. 2008
    ..This review will focus on clinical development of epothilones in breast cancer, particularly ixabepilone which is in the late stages of development, their potential impact in clinical practice, advantages and limitations...
  4. ncbi Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
    ....
  5. ncbi Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
    F Cardoso
    Department of Medicine, Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Int J Gynecol Cancer 16:533-7. 2006
  6. ncbi Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer
    Fatima Cardoso
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:364-9. 2004
    ..88) for Bcl-2-negative disease. Despite its being a retrospective nonrandomized study with a relatively low number of patients, our results suggest that Bcl-2 deserves further evaluation as a predictive factor of sensitivity to tamoxifen...
  7. ncbi Microarray technology and its effect on breast cancer (re)classification and prediction of outcome
    Fatima Cardoso
    Department of Medical Oncology, Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res 5:303-4. 2003
  8. ncbi Targeting the ubiquitin-proteasome pathway in breast cancer
    Fatima Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:148-57. 2004
    ....
  9. ncbi Show me the genes - I will tell you who/how to treat!
    Fatima Cardoso
    Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res 7:77-9. 2005
  10. ncbi The MINDACT trial: the first prospective clinical validation of a genomic tool
    Fatima Cardoso
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Mol Oncol 1:246-51. 2007
    ..This manuscript shortly reviews the rational, design and logistics of MINDACT...
  11. ncbi International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy
    Fatima Cardoso
    Department of Medical Oncology, Medical Oncology and Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    J Natl Cancer Inst 101:1174-81. 2009
    ..Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy...
  12. ncbi Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes
    F Cardoso
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 12:615-20. 2001
    ....
  13. ncbi HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
    E Azambuja
    Department of Medical Oncology and Translational Research Unit Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 19:223-32. 2008
    ..Prospective, randomized trials incorporating important biological hypotheses are either ongoing or just closed, and their results will hopefully help to shed more light on this issue...
  14. ncbi Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer
    C Bernard-Marty
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 14:693-8. 2003
    ..Prolongation of conventional anthracycline-based treatment beyond the current standard of four to six cycles is not recommended in clinical practice...
  15. ncbi Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study
    F Cardoso
    Jules Bordet Institut, Brussels, Belgium
    Anticancer Res 21:789-95. 2001
    ..2) The concomitant use of lenograstin might partially explain the reported incidence of myalgia and arthralgia. 3) No conclusion can be drawn on the most tolerable regimen due to the limited number of patients...
  16. ncbi Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Int J Oncol 25:1473-9. 2004
    ..Although the great majority of topo-II gene aberrations occur in HER-2 positive tumors, the level of HER-2 amplification does not predict for topo-II amplification...
  17. ncbi Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Gynecol Oncol 92:887-95. 2004
    ..In this study, we investigated the actual rates of T2a and HER-2 amplification and overexpression by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively...
  18. ncbi Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
    F Cardoso
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, 1000 Brussels, Belgium
    Int J Oncol 24:201-9. 2004
    ..iii) The role of combined evaluation of several relevant markers and of potential 'molecular signatures' are currently being evaluated in prospective randomized clinical trials...
  19. ncbi Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res Treat 77:199-204. 2003
    ..CONCLUSION: Despite the low number of patients, our results seem to indicate that topo-IIalpha gene status evaluation in the primary breast tumor accurately reflects its status in the corresponding distant metastases...
  20. ncbi Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
    A Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Br J Cancer 98:1500-7. 2008
    ..Bortezomib plus docetaxel is an active combination for anthracycline-pretreated advanced/metastatic breast cancer. The safety profile is manageable and consistent with the side effects of the individual agents...
  21. ncbi Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
    ..65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC...
  22. ncbi Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..88 and 0.89, respectively. CONCLUSIONS: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer...
  23. ncbi 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study
    Antonio Fabiano Ferreira Filho
    Jules Bordet Institute, Brussels, Belgium
    Anticancer Res 22:2471-6. 2002
    ..CONCLUSION: The efficacy of these docetaxel-based regimens, in terms of OS and DFS, appears to be at least as good as standard anthracycline-based adjuvant chemotherapy (CT), in similar high-risk patient populations...
  24. ncbi Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer
    Fatima Cardoso
    Jules Bordet Institute, Brussels, Belgium
    Drugs Today (Barc) 39:399-414. 2003
    ..In this article, the authors analyze in detail some of these landmark studies of adjuvant endocrine and cytotoxic therapy, emphasizing their strengths and weaknesses...
  25. ncbi The pipeline of new anticancer agents for breast cancer treatment in 2003
    A Awada
    Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 48:45-63. 2003
    ..This review will focus on new agents, cytotoxic, hormonal and molecular-targeted, which are in advanced clinical stages of development for the treatment of MBC...
  26. ncbi The best use of chemotherapy in the adjuvant setting
    F Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Breast 12:522-8. 2003
    ..The second question will be the focus of this paper...
  27. ncbi Remaining controversies in the upfront management of advanced ovarian cancer
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 14:707-20. 2004
    ..In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management...
  28. ncbi Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes
    M Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium
    Oncol Rep 12:701-7. 2004
    ....
  29. ncbi New data on chemotherapy in the adjuvant setting
    M J Piccart
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Breast 12:373-8. 2003
    ..The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care...
  30. ncbi Use and abuse of taxanes in the management of metastatic breast cancer
    C Bernard-Marty
    Department of Medical Oncology, Jules Bordet Institute, boulevard de Waterloo, 215, 1000, Brussels, Belgium
    Eur J Cancer 39:1978-89. 2003
    ..Ways of improving taxane-based treatment tailoring both in the pre- and postgenomic eras will be addressed...
  31. ncbi Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer
    M J Piccart
    Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000, Brussels, Belgium
    Eur J Cancer 38:S52-4. 2002
  32. ncbi Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
    D Gancberg
    Translational Research Unit and Data Centre, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 13:1036-43. 2002
    ..These results do not support routine determination of HER-2 on metastatic sites, particularly when FISH results from the primary tumour are available...
  33. ncbi Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Fatima Cardoso
    Chemotherapy and Translational Research Units, Jules Bordet Institute, boulevard de Waterloo, 125 1000 Brussels, Belgium
    Clin Breast Cancer 3:247-57; discussion 258-9. 2002
    ..Moreover, thorough understanding of the HER2 pathway is essential to the identification of new predictive markers of response to trastuzumab that will help to better define the patients who are most likely to benefit from this drug...
  34. ncbi Facts and controversies in the use of trastuzumab in the adjuvant setting
    Phuong Dinh
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Nat Clin Pract Oncol 5:645-54. 2008
    ..This Review outlines the five adjuvant trastuzumab studies and discusses the controversies and challenges that have emerged for both the clinician and healthcare authorities worldwide as a consequence of the results from these trials...
  35. ncbi Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?
    G Atalay
    Jules Bordet Institute, Brussels, Belgium
    Anticancer Drugs 14:703-13. 2003
    ..The conduct of repetitive phase II trials that test minor variations in dose and schedule, while commonplace, does little to advance the field...
  36. ncbi What clinicians need to know about antioestrogen resistance in breast cancer therapy
    Amalia Milano
    Medical Oncology and Translational Research Unit, Jules Bordet Institute, , 1, B-1000 Brussels, Belgium
    Eur J Cancer 42:2692-705. 2006
    ..Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed...
  37. ncbi Molecular targeted therapies in breast cancer: where are we now?
    Christian Widakowich
    Medical Oncology Clinic, Jules Bordet Institute, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Biochem Cell Biol 39:1375-87. 2007
    ..This paper will review the increasing role of molecular targeted therapies in BC, with a particular focus on those drugs currently being tested in early BC, as well as, on future perspectives...
  38. ncbi Recent advances in adjuvant systemic therapy for early-stage breast cancer
    P L Bedard
    Medical Oncology and Translational Research, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 19:v122-7. 2008
  39. ncbi Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
    G Atalay
    Jules Bordet Institute, Department of Medical Oncology, Brussels, Belgium
    Ann Oncol 14:1346-63. 2003
    ..The aim of this review is to provide clinicians with an updated synopsis of the most advanced anti-erbB therapeutic strategies with activity against BC...
  40. ncbi The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative dos
    A F Ferreira Filho
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 13:416-21. 2002
    ..No substantial differences in RDI and cumulative doses were found in relation to a patient's age and the participating institution...
  41. ncbi Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study
    Chantal Bernard-Marty
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 3:341-5. 2002
    ..Nevertheless, further investigations are needed due to the limited number of patients evaluated in this pilot study...
  42. ncbi Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer
    Fatima Cardoso
    Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Cancer Treat Rev 28:275-90. 2002
    ..Two difficult clinical cases, which are representative of those frequently encountered in daily practice, will also be presented and discussed, with the help of a panel of 48 breast cancer experts from different regions of the world...
  43. ncbi Facts and controversies in systemic treatment of metastatic breast cancer
    Chantal Bernard-Marty
    Department of Medical Oncology, Jules Bordet Institute, boulevard de Waterloo, 125, 1000 Brussels, Belgium
    Oncologist 9:617-32. 2004
    ..The potential role of tumor molecular profile(s) in the selection of patients that could benefit the most from each strategy/agent will be discussed...
  44. ncbi Use of trastuzumab for the treatment of early stage breast cancer
    Sofia Braga
    Chemotherapy Unit, Department of Medicine, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 6:1153-64. 2006
    ....
  45. ncbi Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial...
  46. ncbi Chemoprevention for breast cancer
    I Bozovic-Spasojevic
    BIG Breast International Group, Institut Jules Bordet, 121 Blvd de Waterloo, 1000 Brussels, Belgium
    Cancer Treat Rev 38:329-39. 2012
    ..Urgently needed are better molecular risk models to accurately identify high-risk subjects, new agents with a better risk/benefit ratio and validated biomarkers...
  47. ncbi Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma
    A F Ferreira Filho
    Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 12:1757-9. 2001
    ..To our knowledge, this is only the second case of carcinomatous meningitis secondary to a pancreatic carcinoma described so far...
  48. ncbi Molecular profiling of head and neck tumors
    C Sotiriou
    Translational Unit, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 16:211-4. 2004
    ..This article reviews recently reported studies that have used such approaches...
  49. ncbi [News in the medical treatment of breast cancer]
    Martine Piccart
    , Institut Jules-Bordet, 1, Rue Heger-Bordet, 1000 Bruxelles, Belgique
    Bull Cancer 90:46-52. 2003
    ..For each category, the authors will attempt to estimate the impact of the therapeutic advances upon day-to-day clinical practice...
  50. ncbi The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  51. ncbi Bringing molecular prognosis and prediction to the clinic
    Mariantonietta Colozza
    S C Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
    Clin Breast Cancer 6:61-76. 2005
    ....
  52. ncbi Clinical application of the 70-gene profile: the MINDACT trial
    Fatima Cardoso
    Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 26:729-35. 2008
    ..This article reviews the several steps in the development of the profile from its discovery to its clinical validation...
  53. ncbi HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice
    Denis Larsimont
    Pathology Department, Jules Bordet Institute, Brussels, Belgium
    Anticancer Res 22:2485-90. 2002
    ..HER-2/neu status was determined by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) methods in more than 300 paraffin-embedded primary breast cancer samples...
  54. ncbi Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer
    Carolyn Straehle
    Breast International Group, Brussels, Belgium
    Crit Care Med 37:S22-9. 2009
    ....
  55. ncbi Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer
    Philippe L Bedard
    Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, Brussels, Belgium
    Curr Cancer Drug Targets 9:148-62. 2009
    ....
  56. ncbi Multifactorial approach to predicting resistance to anthracyclines
    Christine Desmedt
    Breast Cancer Translational Research Laboratory JC Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, 125 Bld de Waterloo, 1000 Brussels, Belgium
    J Clin Oncol 29:1578-86. 2011
    ....
  57. ncbi Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002
    ..In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined...
  58. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  59. ncbi Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Rosa Giuliani
    Translational Research Unit, Jules Bordet Institute, 125, boulevard de Waterloo, 1000 Brussels, Belgium
    Eur J Cancer 43:725-35. 2007
    ....
  60. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  61. ncbi Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
    Jan Bogaerts
    Medical Oncology and Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Nat Clin Pract Oncol 3:540-51. 2006
    ..We hope that this article will trigger further discussion about the difficulties of setting up and analyzing trials aimed at establishing the worth of new methods for better selection of patients for cancer treatment...
  62. ncbi Achievements in systemic therapies in the pregenomic era in metastatic breast cancer
    Mariantonietta Colozza
    Jules Bordet Institute, Brussels, Belgium
    Oncologist 12:253-70. 2007
    ..In this review we summarize the main achievements and the currently available treatment options for patients with MBC...
  63. ncbi Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  64. ncbi Stemming resistance to HER-2 targeted therapy
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    J Mammary Gland Biol Neoplasia 14:55-66. 2009
    ..Future clinical trials should involve the integration of technologies to assess the impact of novel HER-2 targeted therapies on HER-2 positive CSCs...
  65. ncbi Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing
    David Gancberg
    Translational Research Unit of the Chemotherapy Department, Jules Bordet Institute, Brussels, Belgium
    Breast Cancer Res Treat 74:113-20. 2002
    ..Our data demonstrate that HER-2/neu evaluation by IHC is not a reproducible technique if there is no standardization of the procedure...
  66. ncbi Challenges in breast cancer clinical trial design in the postgenomic era
    Sherene Loi
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Curr Opin Oncol 16:536-41. 2004
    ..The success of new approaches in BC research critically depends on well-conducted translational research linked to prospective clinical trials, and international collaboration, bringing together human and technological resources...
  67. ncbi Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
    Natasa Snoj
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
    Breast Cancer Res 11:201. 2009
    ....
  68. ncbi Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
    Nicola Personeni
    Jules Bordet Institute, Translational Research and Gastroenterology Unit, 1000 Brussels, Belgium
    Semin Oncol 32:S59-62. 2005
    ..8%), showing a trend toward higher disease control in patients with high levels of pEGFR (>or= 7) who were treated with cetuximab with or without irinotecan (P = .05)...
  69. ncbi Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice
    Yan Ma
    Pathology Department, Institut Jules Bordet, Brussels, Belgium
    Clin Cancer Res 11:4393-9. 2005
    ..HER-2/neu status determination by FISH is dependent on the criterion considered for positivity in clinical practice...
  70. ncbi Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
    F Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 13:197-207. 2002
    ..At the turn of the century, in-depth rethinking of the design of clinical trials run in this challenging disease setting appears to be warranted...
  71. ncbi New tools for assessing breast cancer recurrence
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Res 141:99-118. 2008
  72. ncbi Molecular forecasting of breast cancer: time to move forward with clinical testing
    Sherene Loi
    J Clin Oncol 24:721-2; author reply 722-3. 2006
  73. ncbi Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era
    Mariantonietta Colozza
    S.C. Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
    Oncologist 11:111-25. 2006
    ....
  74. ncbi Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
    Carlos M Galmarini
    Universite Claude Bernard Lyon 1, France
    Clin Cancer Res 14:4511-6. 2008
    ..To evaluate the role of microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy...
  75. ncbi [The new generation of breast cancer clinical trials: the right drug for the right target]
    Evandro de Azambuja
    Institut Jules Bordet et l Université Libre de Bruxelles ULB, Service de Medecine, Boulevard de Waterloo 125, B 1000 Bruxelles
    Bull Cancer 95:352-7. 2008
    ..The latter studies, with their strong translational research component, aim to determine which tumour profiles will best benefit from lapatinib as opposed to treatment with trastuzumab alone...
  76. ncbi Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Rd, Nottingham N65 1PB, United Kingdom
    J Clin Oncol 23:5314-22. 2005
    ....
  77. ncbi OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy
    Daniela D Rosa
    J Clin Oncol 24:5176-7; author reply 5177. 2006
  78. ncbi Individualization of therapy using Mammaprint: from development to the MINDACT Trial
    Stella Mook
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Genomics Proteomics 4:147-55. 2007
    ....
  79. ncbi Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Fatima Cardoso
    J Clin Oncol 26:2058-9; author reply 2060-1. 2008